Free aromatherapy (70% menthol and 30% propanediol). All participants will receive the standard inhalation method training before hospital discharge.
The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.

Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.

Percutaneous Coronary Intervention

Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.
The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.

Aromatherapy

Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy

Placebo

ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI)

ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI): a Randomized, Double-blind, Placebo-controlled Trial

Changes in the overall cognitive function in the Aromatherapy group versus changes in the overall cognitive function in the placebo group. MOCA (MOCA-Montreal Cognitive Assessment) will be used to measure the overall cognitive function.

Changes in the memory function in the Aromatherapy group versus changes in the memory function in the placebo group. The test of Word-List Immediate and Delayed Recall will be used to access the memory.

Changes in the executive function of semantic fluency in the Aromatherapy group versus changes in the executive function in the placebo group. Animal Fluency Test will be used to access participants' semantic fluency.

Changes in the executive function of visual attention in the Aromatherapy group versus changes in the executive function in the placebo group. Chinese version of Trails Making Test will be used to access patients' visual attention.

Changes in the orientation function in the Aromatherapy group versus changes in the orientation function in the placebo group. MoCA Orientation function test will be used to access the orientation function.

The proportion of patients with mild cognitive impairment in the Aromatherapy group versus the proportion of patients with mild cognitive impairment in the placebo group.
Mild cognitive impairment is measured by using different cut-off points for cognitive function scores in the Chinese version of MOCA. For participants with low, secondary, and high education levels, mild cognitive impairment is defined as having an overall cognitive function score <19, <22, and <24 respectively. Low education level, secondary education level and high education level are defined as the number of years of education ≤6 years, 7-12 years and > 12 years respectively.

All data of this trial can be obtained on request.

Wei Yongxiang

Director of Beijing Anzhen Hospital

Beijing Anzhen Hospital

Peking University

Randomized (two arms), double-blind, placebo-controlled intervention is proposed in this study. 660 participants undergoing PCI are anticipated to be enrolled from the Beijing Anzhen Hospital. Before hospital discharge, participants will be randomly assigned to receive aromatherapy (70% menthol and 30% propanediol) or placebo (10% menthol and 90% propanediol) after PCI for 6 months.

Participants, investigators, physicians, and outcomes assessors will be blinded to treatment allocation. The sticks of aromatherapy and placebo are the same, and the smell of them is similar. In order to achieve allocation concealment, a web-based central system will automatically assign a random code for each participant. Each bottle of medicine or placebo will be labeled according to the pre-determined random code by an independent agency that does not involve any persons associated with the trial.

Coronary Artery Bypass Grafting

Myocardial Infarction

ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting

ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting (ARCTIC-CABG): a Randomized, Double-blind, Placebo-controlled Trial

Changes in the overall cognitive function in the Aromatherapy group versus changes in the overall cognitive function in the placebo group. MOCA (MOCA-Montreal Cognitive Assessment) will be used to measure the overall cognitive function

Randomized (two arms), double-blind, placebo-controlled intervention is proposed in this study. 460 participants undergoing CABG for the first time are anticipated to be enrolled from the Beijing Anzhen Hospital. Before hospital discharge, participants will be randomly assigned to receive aromatherapy (70% menthol and 30% propanediol) or placebo (10% menthol and 90% propanediol) after CABG for 6 months.

Participants, investigators, physicians, and outcomes assessors will be blinded to treatment allocation. The sticks of aromatherapy and placebo are the same, and the smell of them is similar. In order to achieve allocation concealment, a web-based central system will automatically assign a random code for each participant. Each stick of aromatherapy or placebo will be labeled according to the pre-determined random code by an independent agency that does not involve any persons associated with the trial.

olfaction disorders/infarto

ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI)

ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting

O mais completo banco de dados de ervas medicinais apoiado pela ciência